Radioligand Therapy Market Outlook 2026–2036: Market Size, Growth Drivers, Key Players, Strategic Developments & Adoption Forecast for Lutetium-177 and Actinium-225 Radioligands, Pluvicto Label Expansion, Alpha-Emitter Pipelines, Isotope Supply and Manufacturing Investment — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines how radioligand therapy — a targeting molecule carrying a radioactive isotope to cancer cells, delivering beta or alpha radiation where the tumour is — will move from two approved lutetium-177 products into a broad class of precision oncology over the next ten years, and how isotope supply, manufacturing and consolidation will decide who delivers it. The lead product has proven the model: Novartis's Pluvicto sold USD 651 million in the second quarter of 2026, up 43%, after its March 2025 expansion to pre-chemotherapy castration-resistant prostate cancer, and on 31 July 2026 the FDA approved it for PSMA-positive metastatic hormone-sensitive prostate cancer on PSMAddition data showing a 33% reduction in the risk of progression or death, nearly doubling the eligible population. The industry is building for alpha emitters: NorthStar Medical Radioisotopes reported routine commercial-scale, non-carrier-added actinium-225 production in Beloit in January 2026; TerraPower Isotopes announced a USD 450 million, 250,000 sq ft Philadelphia actinium-225 plant in March 2026 for a 20-fold capacity increase from 2029; Novartis announced radioligand manufacturing sites in Winter Park, Florida and Denton, Texas within a USD 23 billion U.S. plan; and Aktis Oncology raised USD 318 million in a January 2026 IPO anchored by USD 100 million from Eli Lilly. Manufacturing is also the risk: ITM's lutetium-177 edotreotide received an FDA rejection in August 2026 over a third-party commercial facility, and Telix agreed in September 2026 to buy ITM for USD 1.65 billion upfront and up to USD 700 million more, combining pipelines with an isotope supply business that sold USD 273 million in 2025 across more than 65 countries. The brief maps the technology, its indicative market size and forecast, the factors behind its growth, the developments of the last 24 months, the key players operating in the space and the adoption trajectory to 2036.

It is a focused 110-page decision brief for pharmaceutical and radiopharmaceutical companies, isotope producers and contract manufacturers, nuclear medicine and oncology centres, payers, regulators and investors. It presents an indicative trajectory rather than a segmented market model. Its purpose is to identify which targets, isotopes and indications reach approval first, how supply and manufacturing set the pace, and who captures the resulting value.

Radioligand therapy delivers radiation from inside the tumour. A ligand — a small molecule such as PSMA-617, a peptide such as DOTATATE or an antibody — binds a protein expressed on cancer cells and carries a radioactive isotope to them; a matching imaging agent confirms the target is present before treatment. Lutetium-177 emits beta particles that travel a few millimetres and suit larger tumours; actinium-225 and lead-212 emit alpha particles that travel a few cell diameters with far higher energy, killing cells that resist beta radiation and sparing surrounding tissue. Pluvicto, lutetium-177 vipivotide tetraxetan, targets PSMA in prostate cancer; Lutathera targets somatostatin receptors in neuroendocrine tumours; the pipeline adds FAP, HER2, CA9, B7-H3 and other targets and alpha versions of proven ligands.

The evidence now spans the disease course. PSMAddition showed Pluvicto plus an androgen receptor pathway inhibitor reduced the risk of progression or death by 33% (HR 0.67) in hormone-sensitive disease, with an overall survival trend of HR 0.80 pending final analysis, leading to the July 2026 approval that follows the March 2025 pre-chemotherapy expansion and the original post-chemotherapy label; more than 186,000 men a year are diagnosed with metastatic hormone-sensitive prostate cancer across the eight major markets and PSMA is present in more than 80% of prostate cancers. Sales followed: USD 651 million in the second quarter of 2026 alone. Alpha emitters aim to improve on this in resistant disease and new tumour types, which is why Novartis bought Mariana Oncology, Bristol Myers Squibb bought RayzeBio, AstraZeneca bought Fusion, Lilly bought Point Biopharma and anchored Aktis, and Bayer, Sanofi and others hold alpha programmes.

The constraints are isotopes, manufacturing and delivery. Isotopes decay, so they cannot be stockpiled: production, radiolabelling, release testing and shipment must be coordinated to the day, and a manufacturing lapse stops supply or, as ITM found in August 2026, stops approval. Actinium-225 supply has been measured in curies a year; NorthStar's commercial production and TerraPower's 20-fold expansion from 2029 are the first steps to industrial scale, and lutetium-177 depends on reactor and accelerator capacity. Treatment requires licensed nuclear medicine facilities, trained staff and reimbursement, which limits capacity in many health systems. The decade's question is whether supply and manufacturing scale as fast as the clinical evidence.

The radioligand therapy market — therapeutic radioligand product sales, therapeutic isotope supply, radiopharmaceutical contract development and manufacturing and companion diagnostic imaging agents used to select patients — is estimated at USD 3.0–3.6 billion in 2026, led by Pluvicto and Lutathera, PSMA and somatostatin imaging agents, lutetium-177 and early actinium-225 supply and contract manufacturing. Meticulous Next™ expects it to reach USD 15–20 billion by 2036, an indicative CAGR of 17–19%. Growth is driven by Pluvicto's expansion across metastatic prostate cancer, by competing lutetium PSMA products and ITM-11 in neuroendocrine tumours after manufacturing is resolved, by the first actinium-225 and lead-212 approvals around 2028 to 2030, by new targets in breast, lung, kidney and gastrointestinal cancers, by industrial-scale actinium supply from 2029 and by treatment-centre expansion. The forecast is sensitive to isotope supply, manufacturing qualification and reimbursement. The United States leads on approvals, sales, isotope investment and treatment capacity; Europe leads on isotope production through ITM, Eckert & Ziegler, PanTera and SCK CEN and on early adoption; Australia contributes Telix and AdvanCell; Japan and China build domestic supply and trials.

The base case assumes PSMA radioligands expand through 2028, first alpha approvals around 2029, TerraPower and European actinium capacity online by 2029–2030 and manufacturing issues resolved. An accelerated case adds strong alpha phase 3 results and faster supply, bringing the inflection to 2028 and lifting the 2036 value to the top of the range. A delayed case assumes actinium supply or manufacturing failures, reimbursement limits and alpha safety signals, pushing the inflection to 2031 and confining growth to lutetium products.

Growth drivers

• Clinical proof and label expansion: Pluvicto's 33% risk reduction in hormone-sensitive disease and approval across metastatic prostate cancer.
• Commercial proof: USD 651 million in one quarter, up 43%, and a nearly doubled eligible population.
• Alpha-emitter pipelines backed by Novartis, BMS, AstraZeneca, Lilly, Bayer and a funded cohort of developers.
• Isotope and manufacturing investment: TerraPower's USD 450 million plant, NorthStar's commercial actinium, Novartis's U.S. sites and ITM's supply network.

Enablers

• Companion PSMA and somatostatin imaging that selects patients.
• Accelerator and reactor capacity for lutetium-177 and new actinium-225 routes.
• Reimbursement incentives for domestically produced isotopes and established radioligand coding.
• Capital through IPOs and acquisitions concentrating resources in late-stage programmes.

Restraints and barriers

• Isotope supply limits, especially actinium-225 before 2029, and decay-driven logistics.
• Manufacturing qualification risk, as ITM-11's rejection on a third-party facility showed.
• Treatment-centre capacity, licensing and staffing constraints.
• Reimbursement and cost of therapy in many health systems.

Five converging forces will determine how fast, and how far, radioligand therapy becomes a pillar of oncology: (1) label expansion and new approvals; (2) actinium-225 and lutetium-177 supply; (3) manufacturing and logistics reliability; (4) pharma investment and consolidation; and (5) treatment capacity and reimbursement. The brief assesses each force for direction, speed and confidence.

The key players operating in radioligand therapy include Novartis AG (Advanced Accelerator Applications, Mariana Oncology), Telix Pharmaceuticals Limited, ITM Isotope Technologies Munich SE, Eli Lilly and Company (Point Biopharma), Bristol-Myers Squibb Company (RayzeBio), AstraZeneca PLC (Fusion Pharmaceuticals), Bayer AG, Sanofi S.A., Lantheus Holdings, Inc., Curium Pharma, Eckert & Ziegler SE, NorthStar Medical Radioisotopes, LLC, TerraPower Isotopes, LLC, SHINE Technologies, LLC, Nusano, Inc., PanTera, SCK CEN, Nordion (Sotera Health Company), Isotopia Molecular Imaging Ltd., Aktis Oncology, Inc., ARTBIO AS, AdvanCell Isotopes Pty Ltd, Actithera AS, Nuclidium AG, RadioMedix, Inc., Ratio Therapeutics, Inc., Perspective Therapeutics, Inc., Clarity Pharmaceuticals Ltd, Orano Med, Cellectar Biosciences, Inc., Full-Life Technologies Co., Ltd., Molecular Partners AG, Blue Earth Therapeutics, Ariceum Therapeutics GmbH, Jubilant Radiopharma, Cardinal Health, Inc., PharmaLogic Holdings Corp., Siemens Healthineers AG and GE HealthCare Technologies Inc. The brief profiles representative players in each archetype and assesses which are positioned to deliver radioligand therapy at scale.

The competitive landscape is forming around six archetypes. Pharma owners of approved and late-stage radioligands. Mid-size and emerging radioligand developers with alpha and new-target pipelines. Isotope producers for lutetium-177, actinium-225 and lead-212. Contract manufacturers, radiopharmacies and logistics networks. Imaging and diagnostic providers. Nuclear medicine centres and payers. Competitive intensity is high in 2026 and is expected to concentrate through acquisition and vertical integration through 2030.

Where value migrates.

In 2026 value sits in Pluvicto and Lutathera, companion imaging, lutetium-177 supply and contract manufacturing. By 2029 it moves to PSMA radioligands across prostate cancer, ITM-11 and competitors in neuroendocrine tumours, the first alpha approvals, industrial actinium-225 supply and integrated supply-and-pipeline companies. By 2036 it settles in owners of approved products across several tumour types, isotope producers with alpha capacity, contract manufacturers and logistics networks, companion diagnostic providers and centres that built capacity early. Developers without supply agreements and manufacturers without qualified facilities lose ground.

Capital is flowing through acquisitions, IPOs and plants: Novartis's Mariana purchase, BMS–RayzeBio, AstraZeneca–Fusion, Lilly–Point and the USD 1.65 billion Telix–ITM deal; Aktis's USD 318 million IPO with Lilly's anchor; ARTBIO, AdvanCell, Nuclidium and Actithera rounds tied to supply; TerraPower's USD 450 million plant, NorthStar's commercial actinium and Novartis's U.S. sites. Clinical output is strongest in prostate cancer and neuroendocrine tumours, with alpha and new-target data arriving. Patent and research activity is concentrated in alpha-emitter chelation and stability, lead-212 generators, FAP and new targets, dosimetry and manufacturing automation. The brief tracks four indicators: actinium-225 capacity online, alpha radioligand phase 3 starts and approvals, manufacturing-related regulatory actions and radioligand sales.

The United States leads on approvals, sales, isotope investment and treatment capacity; Europe leads on isotope production and ITM's network; Australia contributes Telix and AdvanCell; Japan and China build domestic supply and trials. Prostate cancer and neuroendocrine tumours lead; breast, lung, kidney and gastrointestinal cancers follow.